Steven Cohen’s Atrium Therapeutics RNA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$239K Buy
+28,917
New +$341K ﹤0.01% 3443
2026
Q2
– Sell
-22,708
Closed -$304K – 4736
2026
Q1
$304K Buy
+22,708
New +$319K ﹤0.01% 3359

Other funds holding RNA

Steven Cohen's RNA Position: Q3 2026 in Review

Steven Cohen opened a new position in Atrium Therapeutics (RNA) in Q3 2026: 28,917 shares worth $239K. The stake represents ﹤0.01% of the portfolio and ranks #3443 among its holdings. This is a return to the name: Steven Cohen previously reported a position in RNA as recently as Q1 2026.

Steven Cohen first reported a position in RNA in Q1 2026 and has held it in 2 quarters since. The position peaked at $304K in Q1 2026. 148 funds tracked by Wall St. Rank hold RNA as of Q3 2026.

  • Steven Cohen held 28,917 shares of Atrium Therapeutics worth $239K as of Q3 2026.
  • Atrium Therapeutics was a new Steven Cohen position in Q3 2026.
  • Atrium Therapeutics made up ﹤0.01% of Steven Cohen's portfolio in Q3 2026, its #3443 holding.
  • Steven Cohen first reported a position in Atrium Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • Steven Cohen's Atrium Therapeutics position peaked at $304K in Q1 2026.
  • 148 funds tracked by Wall St. Rank held Atrium Therapeutics as of Q3 2026.

Based on Point72 Asset Management's 13F filing for Q3 2026, filed 16 Nov 2026.